Acting Attorney General Todd Blanche signed an order last week that moves state-licensed medical cannabis products and prospective FDA-approved cannabis products from Schedule I to Schedule III - a meaningful signal from a federal administration that has historically kept cannabis policy at arm's length. But here's the catch: it is not full rescheduling. Adult-use cannabis remains in Schedule I, the two sides of many dual-license dispensaries are now treated differently under federal law, and the practical implementation of the order is, at best, unclear.
What the Order Actually Does - and Doesn't Do
Schedule III status places medical cannabis alongside substances like certain codeine formulations and ketamine - legal, but regulated. That is a federal policy shift worth noting. The order also covers future FDA-approved cannabis products, though Cat Packer, director of drug markets and legal regulation at the Drug Policy Alliance, points out that the FDA-approval language applies only to drugs that don't yet exist. The few cannabis-derived pharmaceuticals already on the market are not affected. More concerning to Packer: the order appears to predetermine a scheduling outcome for future FDA-approved cannabis drugs without a full evidence-based risk evaluation - which is not how scheduling decisions are supposed to work.
The order leans heavily on the Single Convention on Narcotic Drugs, a 1961 UN treaty requiring that scheduled narcotics - cannabis among them - be produced only in limited quantities and for medical or scientific purposes. That treaty framing is used to justify the medical-only split. Packer, however, notes that Canada has fully legalized cannabis while remaining a signatory to the same convention, suggesting the treaty constraint is more of a policy posture than an absolute legal wall.
A DEA administrative hearing on full rescheduling has been set for June 29. Whether that process results in broader reclassification remains, in Packer's words, "far from guaranteed."
Two Products, Same Room, Different Federal Status
For dispensary operators holding dual licenses - which allow both medical and adult-use sales under one roof - the order creates an operational paradox that is difficult to explain to staff, let alone customers. Ryan Hunter, chief revenue officer at Colorado-based Spherex Labs, put it directly: a patient buying an ounce from the medical side of a dispensary and a recreational consumer buying the same ounce from the adult-use floor are now treated differently under federal law. Same product. Same SKU. Same facility. Same employees running the transaction.
That distinction has implications that run deeper than semantics. If medical cannabis operators can now register with the DEA - one of the order's stated provisions - that opens compliance pathways, potential banking relationships, and possibly 280E relief that adult-use operators cannot access. Section 280E of the Internal Revenue Code disallows standard business deductions for companies trafficking controlled substances, which has long crushed cannabis operators' effective tax rates. Schedule III reclassification, if applied, would remove cannabis from the 280E trap - but apparently only for the medical side of the business. For multi-license operators running medical and adult-use from shared facilities with shared inventory management systems, separating those tax exposures will require a level of accounting precision that most POS and seed-to-sale platforms were not designed to handle across a split federal classification.
Equity Implications and Who Gets Left Out
The medical-first framing does more than create operational headaches - it concentrates the order's benefits in a segment of the industry that was already less accessible. Packer is pointed on this: early medical markets were expensive and difficult to enter, with high licensing fees, facility requirements, and capital demands that excluded many entrepreneurs. Adult-use legalization, and the social equity programs built alongside it, created broader pathways into the industry - particularly for Black and Latino operators who were disproportionately shut out of early medical licensing rounds.
By tying Schedule III protections exclusively to medical licenses, the order effectively delivers federal recognition to the segment of the market with the most institutional capital and the fewest equity licensees. Adult-use operators - including many who entered through equity programs explicitly designed to address the harms of cannabis prohibition - remain Schedule I businesses under federal law. The protection that Packer describes as meaningful for medical patients, that "these products are now federally recognized as legitimate medicine" and that "patients and their caregivers should no longer be treated as criminals under federal law," does not extend to the adult-use consumer buying the identical product two counters over.
What Operators Should Watch Before June 29
The timing of the order is worth examining. With midterms on the horizon and political pressure building around cannabis reform, the announcement reads - to several industry observers - as a strategic move rather than a carefully constructed regulatory instrument. Alex Gonzalez, co-founder and president of packaging company Calyx Containers, said as much, noting that the departure of former Attorney General Pam Bondi, who was considered an obstacle to cannabis policy movement, may have cleared the path for Blanche's order. Whether the June 29 DEA hearing produces a more comprehensive rescheduling framework, or whether the current partial order becomes entrenched as the administration's final position, is the question the entire industry should be tracking.
For medical dispensary operators specifically, the near-term priority is clarity on DEA registration requirements and what Schedule III status actually means for banking access, tax treatment, and compliance documentation. For adult-use operators and brands - particularly those without a medical license - the order changes nothing operationally, and the risk of federal enforcement, however low in practice, remains unchanged on paper. And for operators running both sides of the market, the answer right now is to keep legal counsel close, resist the urge to restructure business entities or inventory systems based on an order whose implementation mechanics are still undefined, and wait to see whether June 29 produces something more workable. Because this version, to put it plainly, does not.
